Dimerix Limited DXB

Dimerix CEO Dr Nina Webster talked with Proactive at the ASX Small and Mid-Cap Conference about its work in kidney disease and what $34 million in funding means for its clinical milestones. Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases with significant unmet medical need. The company’s lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, Dimerix is advancin

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has successfully secured non-dilutive loan facility agreements ("Loan Agreements") with a group of Australian and U.S. based lenders to access up to A$34 million[1] (see key terms in Appendix 1), including the existing A$10 million facility agreement with SKIPTAN.[2]

Dimerix adds DMX-652, a Phase II-ready AKI asset, strengthening its kidney disease pipeline beyond FSGS.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from Mission Therapeutics Limited ("Mission"). The new asset, which expands Dimerix's pipeline in rare kidney disease, is a novel first and best-in-class therapeutic candidate, initially targeting the prevention of acute kidney injury (AKI).

Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB)Mission will receive up to US$292 million in upfront and milestone payments, plus up to double-digit tiered royalties on global net salesDivestment validates Mission's USP30 platform and provides non-dilutive capital to accelerate Mission's lead CNS programme, MTX325, currently in Phase 1 clinical development for Parkinson's d

Everest Medicines has signed an exclusive licensing agreement with Dimerix to develop and commercialize DMX-200 across Asia-Pacific. The deal focuses on treating serious kidney diseases such as focal segmental glomerulosclerosis, an area with significant unmet medical need. This agreement expands Everest Medicines' nephrology pipeline and reinforces its role as a regional player in kidney disease therapies. Everest Medicines (SEHK:1952) has entered this new agreement with Dimerix as the...

In today's Just The Facts.. archTIS has deployed its NC Protect software into the U.S. Department of Defense’s Microsoft DoD365 production environment. The company has also renewed 1,000 licences and says discussions toward a large-scale enterprise agreement are now back on track. Critical Resources has completed its first drilling program at the Cap Burn Gold Project in New Zealand. 11 reverse-circulation holes tested mineralisation beneath a large soil anomaly, marking a low-impact first pass across a one-kilometre strike zone. Telix Pharmaceuticals has delivered an update on its precision m